MichaelMillerMD

PubMed

• 28 citations
  In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
  Simin Xu, Brian P. Doehle, Sonal Rajyaguru, Bin Han, Ona Barauskas
  Antiviral Therapy. 2017-01-01
• 84 citations
  Dyslipidemia and cardiovascular risk: the importance of early prevention
  Michael Miller
  QJM. 2009-06-04
• 1986 citations
  Integrated Genomic Characterization of Papillary Thyroid Carcinoma
  Nishant Agrawal, Rehan Akbani, B. Arman Aksoy, Adrian Ally, Harindra Arachchi
  Cell. 2014-10-23

Journal Articles

• The Present and Future Council Perspectives A Clinician’s Guide for Trending Cardiovascular Nutrition Controversies: Part II  
  Neil F Gordon, Pamela B Morris, Neal D Barnard, Travis Batts, Andrew M Freeman, Michael Miller, Dean Ornish, Caldwell B Esselstyn, Karen Aspry, Kim A Williams, Robert ..., ScienceDirect
• High-Density Lipoproteins: A Consensus Statement from the National Lipid Association  
  Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman J, Cuchel M, D’Agostino RB, Davidson MH, Davidson S, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ, J Clin Lipidol, 1/1/2013
• LDL Cholesterol: The Lower the Better  
  Martin SS, Blumenthal RS, Miller M, Med Clin North Am., 1/1/2012
• Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and HDL composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study  
  Ballantyne CM, Miller M, Kallend D, Niesor E, Am Heart J, 1/1/2012
• Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations  
  Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumentha..., Am J Cardiol., 1/1/2012
• Effects of dalcetrapib in patients with a recent acute coronary syndrome  
  dal-OUTCOMES Investigators, N Engl J Med, 1/1/2012
• Management of lipid disorders: Current and future treatment options  
  Miller M, J Manag Care Med, 1/1/2011
• Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association  
  Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S..., Circulation, 1/1/2011
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy  
  AIM-HIGH Investigators, N Engl J Med, 1/1/2011
• Using omega-3 fatty acids in the practice of clinical lipidology  
  Brown WV, Bays H, Harris W, Miller M, J Clin Lipidol, 1/1/2011
• Exposure to isoflavone- containing soy products and endothelial function: A Bayesian meta-analysis of randomized controlled trials  
  Beavers DP, Beavers KM, Miller M, Stamey J, Messina MJ, Nutr Metab Cardiovasc Dis, 8/14/2010
• Divergent Effects of Joyful and Anxiety-Provoking Music on Endothelial Vasoreactivity  
  Miller M, Mangano CC, Beach V, Kop WJ, Vogel RA, Psychosom Med, 1/1/2010
• The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclero...  
  Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ, J Am Coll Cardiol, 1/1/2010
• Hold the patty, not the lettuce: processing foods for over a quarter century in the Nurses' Health Study  
  Miller M, Circulation, 1/1/2010
• Facing Type 2 diabetes in the healthcare reform era  
  Fendrick AM, Bush MA, Niebylski B, Brunetti LL, Campbell RK, Dunaif A, Fatodu H, Miller M, Rosenzweig JL, Triplett C, Yarnall WJ, Am J Manag Care, 1/1/2010
• Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish  
  Shen H, Damcott CM, Rampersaud E, Pollin TI, Horenstein RB, McArdle PF, Peyser PA, Bielak LF, Post WS, Chang YP, Ryan KA, Miller M, Rumberger JA, Sheedy PF 2nd, Shel..., Arch Intern Med, 1/1/2010
• Cholesterol goals: moving from numbers to treatment  
  Vogel RA, Miller M, Clin Cardiol., 1/1/2009
• Comparative Effects of 3 Popular Diets on Lipids, Endothelial Function and C-Reactive Protein during Weight Maintenance  
  Miller M, Beach V, Sorkin JD, Mangano C, Dobmeier C, Novacic D, Rhyne J, Vogel RA, J Am Diet Assoc, 1/1/2009
• Dyslipidemia and cardiovascular risk: the importance of early prevention  
  Miller M, QJM, 1/1/2009
• Cardiovascular disease: A global problem extending into the developing world  
  Aje TA, Miller M, World J Cardiol, 1/1/2009
• Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome  
  dal-OUTCOMES Committees and Investigators, Am Heart J, 1/1/2009
• Simvastatin Improves Attainment of Low-Density Lipoprotein Cholesterol Target Level in Patients with Type 2 Diabetic Dyslipidemia  
  Dobs A, Miller M, Gazzara RA, Yuan Z, Tershakovec A, J Clin Lipidol, 1/1/2008
• Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives  
  Harris W, Miller M, Tighe AP, Davidson M, Schaefer E, Atherosclerosis, 1/1/2008
• Low High-Density Lipoprotein Cholesterol: An Important Consideration in Coronary Heart Disease Risk Assessment  
  Majeed F, Miller M, Curr Opin Endocrinol Diabetes Obes, 1/1/2008
• Impact of triglyceride levels beyond low density lipoprotein cholesterol after an acute coronary syndrome in the PROVE IT-TIMI 22 Trial  
  Miller M, Cannon C, Murphy SA, Qin J, Ray KK, Braunwald E, for the PROVE IT-TIMI 22 Investigators, J Am Coll Cardiol, 1/1/2008
• Join now to see all

Books/Book Chapters

• Essential Cardiology: Principles and Practice 
  Chapter: Preventive Cardiology. 
  Page 767 - 780Aja TA, Miller MEditors: Clive Rosendorff.W.B. Saunders, PhiladelphiaEdition 3rd,2013
• Preventive Cardiology: A Companion to Braunwald's Heart Disease 
  Chapter: The role of high-density lipoprotein cholesterol in the development of atherosclerotic cardiovascular disease. 
  Page 204 - 215Gandotra P, Miller MEditors: Blumenthal RS, Foody JM, Wong ND.2011
• The Johns Hopkins Textbook of Dyslipidemia 
  Chapter: Disorders of Hypertriglyceridemia. 
  Page 74 - 88Miller MEditors: Kwiterovich PO.Lippincott, Williams & Wilkins, Baltimore, MD2010
• Adult Clinical Cardiology Self-Assessment Program (ACCSAP 7) 
  Chapter: Epidemiology and Global Risk. 
  Limacher MC, Vogel RA, Miller M2009
• Clinical Lipidology: Companion to Braunwald's Heart Disease 
  Chapter: HDL cholesterol in CHD Risk Assessment. 
  Page 119 - 130Miller MEditors: Ballantyne CM.2009
• 2009 Cholesterol Health Planner 
  Miller M, Masterson T, Dawn KInternational Medical Publishing, Inc., McLean, VA2009
• American Medical Association Guide to Preventing and Treating Heart Disease. 
  Lipsky MS, Mendelson M, Havas S, Miller MWiley & Sons, Hoboken, NJ2008
• AMA Guide to Preventing and Treating Heart Disease 
  Chapter: Managing your cholesterol level. 
  Page 23 - 37Miller MWiley & Sons, Inc., Hoboken, NJ2008
• AMA Guide to Preventing and Treating Heart Disease 
  Chapter: Quitting smoking. 
  Page 69 - 75Miller MWiley & Sons, Inc., Hoboken, NJ2008
• AMA Guide to Preventing and Treating Heart Disease 
  Chapter: Eating Healthfully for a lifetime. 
  Page 83 - 99Miller MWiley & Sons, Inc., Hoboken, NJ2008
• AMA Guide to Preventing and Treating Heart Disease 
  Chapter: Overweight and Obesity. 
  Page 99 - 105Miller MWiley & Sons, Inc., Hoboken, NJ2008
• AMA Guide to Preventing and Treating Heart Disease 
  Chapter: Stress. 
  Page 113 - 117Miller MWiley & Sons, Inc., Hoboken, NJ2008
• 2008 Cholesterol Health Planner 
  Miller M, Masterson T, Dawn KInternational Medical Publishing, Inc., McLean, VA2008
• 2007 Cholesterol Health Planner 
  Miller M, Masterson T, Dawn KInternational Medical Publishing, Inc., McLean, VA2007
• 2006 Cholesterol Calendar 
  Miller M, Masterson T, Dawn KInternational Medical Publishing, Inc., McLean, VA2006
• Adult Clinical Cardiology Self-Assessment Program 2006 (ACCSAP 2006) 
  Chapter: Epidemiology, Primary Prevention, and Management of Coronary Heart Disease. 
  Vogel RA, Miller M2006
• Proteins involved in the pathogenesis of atherosclerosis 
  Chapter: Potential role of HDL proteins in modulating atherothrombosis. 
  Page 63 - 81Sura A, Miller MEditors: A. Reiss, S Carsons, B Cronstein.Marcel Dekker, New York2006
• 2005 Cholesterol Planner 
  Miller M , Masterson T, Dawn KInternational Medical Publishing, Inc., McLean, VA2005
• Essential Cardiology 
  Chapter: Preventive Cardiology. 
  Page 801 - 827Miller MEditors: Clive Rosengard.W.B. Saunders, PhiladelphiaEdition 2nd,2005
• 2004 Cholesterol Planner 
  Miller M and Masterson TInternational Medical Publishing, Inc., McLean, VA2004
• Adult Clinical Cardiology self-Assessment Program (ACCSAP 2004) 
  Chapter: Epidemiology and Prevention. 
  Vogel RA, Miller M2004
• 2003 Cholesterol Planner 
  Miller M and Masterson TInternational Medical Publishing, Inc., McLean, VA2003
• Acute Coronary Syndromes 
  Chapter: Statins and Plaque Stabilization. 
  Page 507 - 548Miller M, Vogel RAEditors: E. Topol.Marcel Dekker, New YorkEdition 3rd,2003
• 2002 Cholesterol Planner 
  Miller M and Masterson TInternational Medical Publishing, Inc., McLean, VA2002
• Adult Clinical Cardiology self-Assessment Program (ACCSAP 2002) 
  Chapter: Epidemiology and Prevention. 
  Vogel RA, Miller M2002
• Join now to see all

Abstracts/Posters

• Low HDL-C and Prediction of CHD Risk in Subjects with Normal TG and LDL-C Levels. The Framingham Offspring Study.
  Miller M, Kim Y, Havas S, Kwiterovich PO, Fazio S, 64th Annual Scientific Sessions of the American College of Cardiology, Washington, DC, 3/31/2014
• Remnant cholesterol predicts short and long-term recurrent ischemic events after acute coronary syndrome.
  Schwartz GG, Abt M, Bao W, DeMicco D, Miller M, Mundl H, Olsson AG, 64th Annual Scientific Sessions of the American College of Cardiology, Washington, DC, 3/31/2014
• Does the Metabolic Syndrome Cluster Provide Incremental Prognostic Information Over the Individual Components? Post Hoc Analysis of the AIM-HIGH Trial.
  Boden WE, Robinson JG, Miller M, Simmons D, Xu S, Abramson B, Elam MB, Nash SD, Brown TM, McBride, Fleg JL, Desvigne-Nickens P, Probstfield JL, 75th Annual Scientific Sessions of the AHA, Dallas, TX, 11/1/2013
• Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations.
  Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumentha..., Johns Hopkins CME Summit: “Preventing CV Disease Through Dyslipidemia Management: an Educational Summit”, Baltimore, MD, 6/26/2013
• Effects of Dalcetrapib in combination with pravastatin on lipoprotein profile in patients with Type II dyslipidemia.
  Miller M, Ballantyne CM, Niesor EJ, Burgess T, Kallend D, Stein EA, 78th European Atherosclerosis Society Congress, Hamburg, Germany, 6/21/2010
• Effect of Dalcetrapib plus Pravastatin on Lipoprotein Metabolism in Dyslipidemic Patients: Results of a Phase 2b Dose-ranging Study.
  Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA, 60th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, 3/14/2010
• Association of HDL-C candidate genes with HDL-C and coronary artery calcification.
  Shen H, O’Connell JR, Bielak LF, Peyse PA, Post W, Ryan KA, Gibson Q, Miller M, Shuldiner AR, Mitchell BD, 50th AHA Cardiovascular Disease Epidemiology and Prevention and Nutrition, Physical Activity and Metabolism, San Francisco, CA, 3/2/2010
• ARBITER 6-HALTS: The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness.
  Taylor AJ, Villines TC, Devine PJ, Turco M, Griffen L, Miller M, Stanek EJ, Weissman NJ, Late Breaking Clinical Trial at the 71st Annual Scientific Sessions of the American Heart Association, Orlando, FL, 11/16/2009
• Apolipoprotein C-III deficiency reduces dyslipidemia in the presence of insulin resistance.
  Pollin T, Damcott CM, Mitchell BD, Miller M, Shuldiner AR, 59th Annual Scientific Sessions of the American Society of Human Genetics, Honolulu, HW, 10/22/2009
• Positive emotions and the endothelium: Does joyful music improve vascular health?
  Miller M, Beach V, Mangano C, Vogel RA, 70th Annual Scientific Sessions of the American Heart Association; Circulation, New Orleans, LA, 11/11/2008
• Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia.
  Dobs A, Miller M, Delucca PT, Ramsey KE, Tershakovec AM, Horn W, J Clin Lipidol, 2/1/2008
• Multiple Splice Defects in ABCA1 cause Low HDL-C in a family with Premature Coronary Disease.
  Rhyne J, Mantaring M, Gardner DF, Miller M, 57th Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, 3/26/2007
• Is isolated low HDL an atherogenic phenotype? The Amish Family Calcification Study.
  Shen H, Miller M, Bielak LF Peyser PA, Shuldiner AR, Mitchell BD, 69th Annual Scientific Sessis of the American Heart Association; Circulation, Orlando, FL, 1/1/2007
• Comparative Effects of 3 Popular Diets on Lipids, Endothelial Function and Biomarkers of Atherothrombosis in the Absence of Weight Loss.
  Miller M, Beach V, Mangano C, et al., 69th Annual Scientific Sessis of the American Heart Association; Circulation, Orlando, FL, 1/1/2007
• The APOB R3500Q polymorphism is common in the Old Order Amish and is a major cause of increased low density lipoprotein cholesterol (LDL-C) concentrations and coronar...
  Shen, H, Damcott CM, Rampersaud E, Pollin TI, O’Connell JR, McArdle P, Peyser PA, . Bielak LF, Ryan KA, Miller M, Shelton J, Shuldiner AR, Mitchell BD, 69th Annual Scientific Sessions of the American Heart Association; Circulation, Orlando, FL, 1/1/2007
• Novel and Common SNPs in the ABCA1 Gene in Association with Low and High HDL-C.
  Mantaring M, Rhyne J, Miller M, 12th Annual Scientific Meetings of the Association of Molecular Pathology, Orlando, FL, 11/16/2006
• Impact of Triglycerides in PROVE-IT TIMI-22: Does TG <150 Improve CHD Risk Beyond LDL <70?
  Miller M, Cannon CP, Kausik KR, Murphy S, Qin J, Braunwald E, 78th Annual Scientific Sessions of the American Heart Association, Chicago, IL, 11/15/2006
• Simvastatin Improves Attainment of Low-Density Lipoprotein Cholesterol Target Level in Patients with Type 2 Diabetic Dyslipidemia.
  Dobs A, Miller M, Gazzara RA, Yuan Z, Tershakovec A, Annual Scientific Sessions of the American Endocrine Society, 1/1/2006
• Impact of triglyceride lowering on HDL-C: Is there a continuum of HDL-C increase beyond fasting TG < 150 mg/dL.
  Miller M, Langenberg P, Havas S, 56th Annual Scientific Sessions of the American College of Cardiology; JACC, Atlanta, GA, 1/1/2006
• The APOC3 promotor polymorphisms T-455C and C-482T are associated with the Metabolic Syndrome.
  Miller M, Zhan M, Rhyne J, Aggawral M, Misra A, 55th Annual Scientific Session of the American College of Cardiology; JACC, Orlando, FL, 1/1/2005
• Simvastatin improves triglyceride-rich lipoproteins in patients with Type 2 diabetes, low HDL-C and elevated TG: A substudy of the SILHOUETTE trial.
  Miller M, Dobs A, Yuan Z, Battisti W, Palmisano J, 55th Annual Scientific Session of the American College of Cardiology; JACC, Orlando, FL, 1/1/2005
• Divergent effects of laughter and mental stress on endothelial function: Potential impact of entertainment.
  Miller M, Mangano C, Goel R, Park Y, Plotick G, Vogel RA, 55th Annual Scientific Session of the American College of Cardiology; JACC, Orlando, FL, 1/1/2005
• Statins inhibit platelet PAR-1 thrombin receptor in patients with metabolic syndrome: The PAR-1 Inhibition by Statins (PARIS) Trial.
  Serebruany VL, Miller M, Malinin AI, Pokov AN, Lowry DR, Tanguay J-F, Hennekens CH, European Society of Cardiology, Stockholm, 1/1/2005
• Identification of Novel SNPs in the ABCA1 gene.
  Mantaring MM, Rhyne J, Miller M, 10th Annual Scientific Meetings of the Association of Molecular Pathology, Los Angeles, CA, 11/13/2004
• Rarity of High CRP in the Absence of CHD Risk Factors: Evidence against Widespread CRP Screening.
  Miller M, Zhan M, 77th Annual AHA Scientific Sessions, New Orleans, LA, 1/1/2004
• Join now to see all

Lectures

• “Medications should routinely be used to treat triglycerides between 200-500 mg/dL." Protagonist; (Sanjay Kaul, Antagonist). 
  3/30/2014
• PriMed Update: Managing the patient with high triglycerides; Assessment and Treatment Strategies. 
  Ft. Lauderdale, FL - 2/6/2014
• Cardiovascular Disease Arena-Focus on Glycemic Control 
  Dallas, TX - 11/18/2013
• Recent Advances and Emerging Data in the Treatment of Hypertriglyceridemia. 
  Las Vegas, NV - 11/15/2013
• Undertreated Stroke Prevention in Atrial Fibrillation: The risk of bleeding versus the risk of stroke. 
  Las Vegas, NV - 11/15/2013
• Advanced Lipids & Hypertension Management; 3rd Annual Update 
  Udaipur, India - 9/21/2013
• “Preventing CV Disease Through Dyslipidemia Management: an Educational Summit” 
  Baltimore, MD - 6/26/2013
• “Unpeeling Current Controversies of Lipid Management” 
  Chicago, IL - 6/22/2013
• “Controversial Issues and Challenging Cases in Hypertriglyceridemia” 
  Las Vegas, NV - 5/30/2013
• “Tackling the toughest issues and cases of hypertriglyceridemia” 
  Washington, DC - 5/21/2013
• “Tackling the toughest issues in HTG” 
  San Francisco, CA - 4/11/2013
• “Basic Education on Assessment and Treatment of Hypertriglyceridemia" 
  Garden City Hospital, Garden City, MI - 2/15/2013
• “Update on HTG states” 
  Ft. Lauderdale, FL - 2/7/2013
• “Assessment and Treatment of HTG” 
  Philadelphia, PA - 1/23/2013
• “Update on the science of HDL therapy” 
  Indianapolis, IN - 12/12/2012
• “From Crisis Management to New Opportunities in Cardiovascular Care" 
  Baltimore, MD - 12/5/2012
• “Preventing Cardiovascular Disease by Dyslipidemia Management: State of the Art” 
  Los Angeles, CA - 11/5/2012
• “Update in Preventive Cardiology” 
  Hackensack University Medical Center, Hackensack, NJ - 10/22/2012
• The Heart of Lipid Disorders. 
  University of New Mexico, Albuquerque, NM - 10/13/2012
• “Update in Lipids” 
  Washington, DC - 9/22/2012
• “Genetic Causes of HTG” 
  Charlotte, NC - 9/15/2012
• “Update in Lipid Management” 
  RWJ University Hospital at Rahway, Rahway, NJ - 9/5/2012
• “CVD Reduction and Lipid Management” 
  Good Samaritan Hopsital, Baltimore, MD - 6/27/2012
• “Addressing Dyslipidemia Management Challenges in T2DM Patients” 
  Philadelphia, PA - 6/9/2012
• “Managing Acute Coronary Syndromes” and “Unmet Needs of Atrial Fibrillation” 
  Orlando, FL - 4/27/2012
• Join now to see all

Other

• Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control. 
  Wright RS, Miller M, Rosenson RS, Cardiology Today Monograph
  http://www.healio.com/cardiology/education-lab/2014/02_february/risk-management-in-the-cardiovascular-disease-arena/cme-information
  2/1/2014
• Exploring the Mechanism of Action of Omega-3 Fatty Acids and the Potential Impact on CVD Risk Reduction CME. 
  Miller M, Ansell BJ, Bays HE, Medscape
  http://www.medscape.org/viewarticle/808286
  1/1/2013
• Triglycerides and Cardiovascular Disease in the T2DM Patient and Understanding Key Elements of Residual Cardiovascular Risk in T2DM Patients. 
  Miller M, Haffner SM, Medscape
  http://www.medscape.org/viewarticle/769145
  1/1/2012
• Choose statin combination over higher-dose statin. 
  Miller M, Practical Lipidology
  1/1/2012
• Recognizing and Managing Residual Risk: Considering the Role of HDL in CV Disease. 
  Jones PH, Miller M, Smith DA, Medscape
  http://www.medscape.org/viewarticle/769317
  1/1/2012
• Clinical Consults: Addressing Dyslipidemia Management Challenges in T2DM Patients—Improving Outcomes Through Guided Patient Solutions (GPS). 
  Miller M, Rosenson RS, Eckel RH, Haffner SM, Medscape
  http://www.medscape.org/viewprogram/32581
  1/1/2012
• Improving Patient Adherence: Practical Strategies for Secondary Prevention. 
  Ferdinand KC, Miller M, Berra K, Morris A, Medscape
  http://www.medscape.org/viewprogram/32094
  1/1/2011
• New Directions in the Treatment of Mixed Dyslipidemia and its Residual Risk. 
  Ballantyne CM, Schafer E, Miller M, Bays H, Medscape
  http://www.medscape.org/viewarticle/754059
  1/1/2011
• Improving Patient Compliance: Communicating the Importance of Lifestyle Modification for Secondary Prevention. 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/746776
  1/1/2011
• The Burden of Cardiovascular Disease: Why Secondary Prevention Is Critical. 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/746983
  1/1/2011
• Healthy lifestyle behaviors and triglycerides. 
  Miller M, Kris-Etherton PM, Stone N, Clinical Nutrition Insight
  1/1/2011
• Late-breaking developments in the treatment of dyslipidemia: Are all omega-3 fatty acids the same? 
  Miller M, Schaefer EJ, Jacobson TA, Bays HE, Medscape
  http://www.medscape.org/viewarticle/755392
  1/1/2011
• Integration of Dietary Recommendations for Patients With Hypertriglyceridemia. 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/589408
  1/1/2009
• Is There a Relationship Between Hypertriglyceridemia and High Uric Acid Levels? 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/703290
  1/1/2009
• Triglycerides in Cardiovascular Disease-Does lowering triglyceride level result in additional benefit beyond lowering LDL-C to target levels? Triglyceride Reduction Be... 
  Miller M, Medscape
  http://www.medscape.com/viewarticle/587221
  1/1/2009
• Triglycerides in Cardiovascular Disease-What are the effects of statins on triglycerides and what are the results of major outcome studies? 
  Miller M, Medscape
  http://www.medscape.com/viewarticle/589010
  1/1/2009
• Triglycerides in Cardiovascular Disease-What is the association between the triglyceride to high-density lipoprotein cholesterol ratio and insulin resistance? 
  Miller M, Medscape
  http://www.medscape.com/viewarticle/588474
  1/1/2009
• What are the effects of statins on triglycerides and what are the results of major outcomes studies? 
  Miller M, Medscape
  http://cme.medscape.com/viewarticle/589010
  1/1/2009
• Is There an Independent Association Between Lowering Triglycerides and Increasing High-Density Lipoprotein Cholesterol? 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/701859
  1/1/2009
• Hypercholesterolemia. 
  Engelhardt M, Miller M, BMJ Point of Care (Epocrates)
  https://online.epocrates.com/noFrame/showPage.do?method=diseases&MonographId=170&ActiveSectionId=11
  1/1/2008
• Epidemiologic evidence supports triglycerides as an independent risk biomarker for coronary disease. In Emerging Data in the Treatment of Mixed Dyslipidemia. 
  Miller M, Cardiology Today
  1/1/2008
• Triglycerides in Cardiovascular Disease-Triglyceride Reduction Below 150 mg/dL. 
  Miller M, Medscape
  http://www.medscape.com/viewarticle/571759
  1/1/2008
• Classification of the Hypertriglyceridemic Patient: Are All Patients With Elevated Triglycerides at Increased Risk for Coronary Heart Disease? 
  Miller M, Medscape
  http://www.medscape.org/viewarticle/580982
  1/1/2008
• Signs and symptoms of dyslipidemia. 
  Miller M, Medscape
  1/1/2008
• Striking the Right Balance Treating Beyond LDL: Effective Management of Dyslipidemia and Metabolic Syndrome. 
  Bittner V, Kountz DS, Miller M, Sacks FM, Duch D
  http://cme.medscape.com/viewprogram/17789?src=cmemp
  1/1/2008
• Join now to see all